U.S. Food and Drug Administration Approves Chemo-Free Therapy for Relapsed/Refractory Indolent Lymphomas
On May 28, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of lenalidomide (REVLIMID, Celgene Corporation) in combination with rituximab (RITUXAN, Genentech, Inc.) for the treatment of adult patients with relapsed or refractory follicular…